Helix BioPharmaHBPCF 28 PB Ratio is 12.21 as of Jun. 25, 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 1,233 Biotechnology companies, Helix BioPharma ranks worse than 79.16% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Helix BioPharma's share price is $1.71. Helix BioPharma's Book Value per Share for the quarter that ended in Apr. 2026 was $0.14. Hence, Helix BioPharma's PB Ratio of today is 12.21.
The historical rank and industry rank for Helix BioPharma's PB Ratio or its related term are showing as below:
HBPCF'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 6.93
Current: 6.93
During the past 13 years, Helix BioPharma's highest PB Ratio was 6.93. The lowest was 0.00. And the median was 0.00.
HBPCF's PB Ratio is ranked worse than 79.16% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs HBPCF: 6.93
During the past 3 years, the average Book Value Per Share Growth Rate was 185.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Helix BioPharma was 185.80% per year. The lowest was -35.10% per year. And the median was -9.25% per year.
Back to Basics: PB Ratio
Helix BioPharma (OTCPK:HBPCF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Helix BioPharma PB Ratio Related Terms
Helix BioPharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Helix BioPharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Helix BioPharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Helix BioPharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Helix BioPharma (HBPCF) has a PB Ratio of 12.21 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Helix BioPharma and its competitors. According to the industry distribution chart, Helix BioPharma ranks #976 out of 1233 companies in the Biotechnology industry, placing it in the top 79.2%.
Is Helix BioPharma's PB Ratio too high?
Helix BioPharma's current PB Ratio is 12.21. The Biotechnology industry median PB Ratio is 2.80. Helix BioPharma's value of 12.21 is 336.1% above this industry median. Based on the distribution chart, Helix BioPharma ranks #976 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #976 out of 1233 companies for PB Ratio. This places Helix BioPharma in the lower half of its industry. The industry median PB Ratio is 2.80. Helix BioPharma's value of 12.21 is 336.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Helix BioPharma's current PB Ratio of 12.21 is 336.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Helix BioPharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helix BioPharma's current PB Ratio is 12.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current PB Ratio of 12.21. The current PB Ratio is 12.21 and 336.1% above the Biotechnology industry median of 2.80. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current PB Ratio is 12.21 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score
Get the complete analysis for HBPCF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 
